Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SANTORINI-MX: Lipid Management Gaps in Mexican Patients at High and Very High Cardiovascular Risk

NCT07930975 is registered in ClinicalTrials.gov with Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07930975 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
SANTORINI-MX: Lipid Management Gaps in Mexican Patients at High and Very High Cardiovascular Risk
Lead sponsor
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Phase
Observational
Overall status
Not yet recruiting
Start date
January 1, 2027
Completion date
February 28, 2029
Enrollment
1,600 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

Arms

As registered; 1 arm.

  • High and Very High Cardiovascular Risk Patients Lipid-Lowering Therapy in Routine Clinical Practice

    Adults aged 18 years or older classified as having high or very high cardiovascular risk according to the 2019 ESC/EAS guidelines, who are receiving or have a clinical indication for lipid-lowering therapy. Participants will be consecutively enrolled at participating healthcare centers in Mexico and assessed at baseline and after 12 ± 2 months. Lipid levels, cardiovascular risk factors, lipid-lowering treatments, treatment intensification, medication adherence, and barriers to optimal lipid management will be recorded. All treatments will be prescribed according to routine clinical practice, without protocol-assigned interventions.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Proportion of Participants Achieving Risk-Based LDL-C Treatment Goals Baseline (at enrollment; LDL-C measurement obtained within the preceding 12 months)

    The percentage of participants achieving low-density lipoprotein cholesterol (LDL-C) targets according to their cardiovascular risk category, as defined by the 2019 ESC/EAS guidelines: LDL-C below 70 mg/dL for high-risk participants and below 55 mg/dL for very-high-risk participants. The numerator will be the number of participants achieving their corresponding risk-based LDL-C target, and the denominator will be the number of evaluable participants with baseline LDL-C data. Results will be reported overall and stratified by cardiovascular risk category, with 95% confidence intervals.

Lead sponsor's other trials

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, most recent start first.

Similar trials

Same condition (Hypercholesterolemia) and phase, most recent start first.